Increasing evidence suggests that Toll-like receptor 4 (TLR4) contributes importantly to spinal cord glial activation and chronic pain sensitization; however, its unique role in acute and chronic itch is unclear. In this study, we investigated the involvement of TLR4 in acute and chronic itch models in male mice using both transgenic and pharmacological approaches. Interestingly, scratching plays an essential role in spinal astrogliosis, since AEW-induced astrogliosis was abrogated by putting Elizabethan Collars on the neck to prevent scratching the itchy skin. Our findings suggest that spinal TLR4 signaling is important for spinal astrocyte activation and astrogliosis that may underlie alloknesis and chronic itch.
Introduction
Toll-like receptors (TLRs) are evolutionarily conserved type I transmembrane proteins that can mediate innate and adaptive immunity via recognition of exogenous ligands, pathogen-associated molecular patterns (PAMPs) following viral and bacterial infection as well as detection of endogenous ligands, danger-associated molecular patterns (DAMPs) produced after tissue injury [2;50] . Different TLRs detect distinct PAMPs and DAMPs. For example, TLR3 and TLR7/8 sense double-stranded and single-stranded RNAs, respectively and TLR4 binds to lipopolysaccharide (LPS) [33] . Most TLRs (except TLR3) signal through the intracellular adaptor protein MyD88 [3;6] . In immune or glial cells, activation of TLRs produces a wide array of pro-inflammatory mediators, including cytokines and chemokines, as well as reactive oxygen/nitrogen intermediates, via activation of NF-κB and MAP kinase pathways [33] . TLR4 is the best studied member of the TLR family. Emerging evidence supports an important role of TLR4 in spinal cord glial activation in neuropathic pain [60] and chronic arthritis pain [9] .
Additionally, spinal TLR4 was implicated in opioid-induced glial activation [20] .
TLR4/MyD88 in DRG neurons was also involved in chemotherapy-induced neuropathic pain [31] . However, the role of TLR4 in different chronic itch conditions has not been investigated.
Glial cells such as microglia and astrocytes have been shown to play an important role in promoting chronic pain [11;16;39] . Chronic pain could be a result of gliopathy [25] . It is generally believed that glia promote pain by producing proinflammatory and pronociceptive mediators (e.g., proinflammatory cytokines and chemokines and growth factors) to activate and sensitize spinal cord nociceptive neurons [26;27;63] . Despite a prominent role of glial cells in the genesis of chronic pain, it is unclear how glial cells regulate itch. During the submission of the manuscript for this study, Shiratori-Hayashi et al. demonstrated an important role of reactive spinal cord astrocytes in chronic itch via astrocytic activation of the transcriptional factor STAT3 [53] .
Itch and pain are two distinct somatic sensations, but they also share many similarities [4;18;29;34;36;47;68;69] . Itch evokes scratching response, while pain elicits intrathecally to target spinal cord cells: LPS-RS (20 µg) and L-AA (100 nmol) [70] .
Intrathecal injection was performed by a lumbar puncture to deliver reagent into cerebral spinal fluid. A valid spinal puncture was confirmed by a brisk tail-flick after the needle entry into subarachnoid space [21] . We injected LPS or L-AA 24 hours before itch assay and injected LPS-RS 30 min prior to itch assay. Reagents were dissolved in sterile saline as vehicle if not specified.
Behavioral analysis

Neck models of acute itch.
Mice were habituated to testing environment daily for two days before analysis. The back of the neck of animals were shaved on the day before testing. Mice were put in plastic chambers (14 × 18 × 12 cm) on an elevated metal mesh floor and allowed 30 min for habituation. We intradermally injected 50 µl of pruritic agents in the nape of neck and video-recorded scratching behavior for 30 min in the absence of any observer. A scratch was counted when a mouse lifted its hindpaw to scratch the shaved region and returned the paw to the floor or to the mouth for licking.
The following doses for pruritic agents were chosen: 100 µg for compound 48/80 and 200 µg for chloroquine. The spontaneous itch was video-recorded and assessed blindly.
Cheek models of acute itch.
The cheek model was developed to distinguish itch and pain [52] . We shaved mouse cheek (approx. 5×8 mm) two days before experiments. On the day of experiment, after brief anesthesia with isoflurane, we injected 10 µl of reagent (100 µg compound 48/80 or 200 µg chloroquine) into the cheek and counted the number of wipes and the number of scratches for 30 min. We counted the unilateral wipes with the forelimb. We also counted scratches, which were defined as a lifting of the hind paw toward the injection site on the cheek and then returning the paw to the floor or to the mouth.
Dry skin-induced chronic itch in the neck and cheek.
We produced a dry skin model to induce chronic itch, as described previously [42] , by painting the neck or cheek skin with acetone and diethyether (1:1) following by water (AEW) twice a day (9:00 am and 16:00 pm) for 5 days. The spontaneous scratching was video recorded for 1 hour on day 6 and total number of scratches was counted blindly. As previously reported [23] , we let mouse wear an Elizabethan Collar on the neck to prevent mouse from A C C E P T E D scratching the cheek skin so that we can test the effect of scratching on AEW-induced spinal cord astrogliosis.
DNFB-induced allergic contact dermatitis in neck skin.
We generated the allergic contact dermatitis (ACD) model of chronic itch by applying the hapten 1-fluoro-2, 4-dinitrobenzene (DNFB) onto the back skin as previously described [30] . DNFB was dissolved in a mixture of acetone:olive oil (4:1). The surface of abdomen and the nape of neck were shaved 1 day before sensitization. Mice were sensitized with 50 µl 0.5% DNFB solution by topical application to a 2 cm 2 area of shaved abdomen skin. 5 days later, mice were challenged with 30 µl 0.25% DNFB solution by painting the nape of neck, then on day 1, 3, 5, and 7. Spontaneous scratching behaviors were video-recorded on day 8 for 60 min.
DCP-induced contact dermatitis in neck skin.
To induce contact dermatitis,
we shaved the back of neck and painted the back with 0.2 ml of diphenylcyclopropenone (DCP; 1% dissolved in acetone) [58] . Seven days after the sensitization, we challenged mice by painting the back skin with 0.2 ml of 0.5% DCP.
Mouse itch behavior was video-recorded for 60 minutes immediately after each DCP application.
Alloknesis assay in neck and cheek models.
According to a previous report [5] , alloknesis after acute itch and chronic itch was evaluated. For testing alloknesis after acute itch, a von Frey filament (0.7 mN) was applied to the skin area 5 mm outside the injection site and 30 min after the compound 48/80 injection. A scratch bout directed to the site of mechanical stimulation was considered as a positive response. The alloknesis score was determined by calculating the total number of scratches elicited by five mechanical stimuli and was evaluated at 10-min intervals post-injection. For testing alloknesis in dry skin model, von Frey stimuli were applied at the border of the AEW treatment area 12 hours after each treatment to elicit scratching response.
Hot plate test.
The hot plate was set at 52 o C. A mouse was put on the plate and the latency for the mouse to lick a hindpaw or jump from the hot plate was recorded.
Patch clamp recordings in DRG neurons
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DRGs were removed aseptically from mice (4-6 weeks) and incubated with collagenase (1.25mg/ml, Roche)/dispase-II (2.4 units/ml, Roche) at 37°C for 90 min, then digested with 0.25% trypsin for 8 min at 37°C, followed by 0.25% trypsin inhibitor. Cells were mechanically dissociated with a flame polished Pasteur pipette in the presence of 0.05% DNAse I (Sigma). DRG cells were plated on glass cover slips and grown in a neurobasal defined medium (with 2% B27 supplement, Invitrogen) with 5 µM AraC and 5% carbon dioxide at 36.5°C. DRG neurons were grown for 24 hours before use. As we previously reported [45] , whole-cell patch clamp recordings were performed at room temperature using an Axopatch-200B amplifier (Axon Instruments). The patch pipettes were pulled from borosilicate capillaries (Chase Scientific Glass Inc.). Pipette resistance was 4-6 MΩ.
Immunohistochemistry
As we previously reported [8] , mice were terminally anesthetized with isoflurane and perfused through the ascending aorta with PBS followed by 4% paraformaldehyde. After 
Real-time quantitative RT-PCR
We rapidly collected cervical spinal cord in RNase-free conditions and isolated total RNAs using RNeasy Plus Mini kit (Qiagen, Valencia, CA). RNA (1 µg) was reversetranscribed for each sample using SuperScript III RT (Invitrogen). The sequences of the forward and reverse primers for
Iba1:
Forward: GGACAGACTGCCAGCCTAAG;
Reverse: GACGGCAGATCCTCATCATT;
Gfap:
Forward: GAATCGCTGGAGGAGGAGAT;
Reverse: GCCACTGCCTCGTATTGAGT; , and a DNA melting curve was included to test the amplicon specificity. Triplicate qPCR analyses were performed using the SYBR Green master mix (KAPA) and Opticon real-time PCR Detection System (Bio-Rad, Hercules, CA) as described previously [7] .
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Statistical analysis
All the data were expressed as mean + SEM. Behavioral data were analyzed using Student's t test or one-way ANOVA followed by Dunn's post hoc test. Two-Way repeated measured ANOVA with post hoc Bonferroni's test was used to analyze two group data with multiple time points. The criterion for statistical significance was set at P<0.05.
Results
Acute itch is not affected after Tlr4 deletion and spinal inhibition of TLR4
We first employed genetic and pharmacological approaches to assess the involvement of (Fig. 1D ). Thus, TLR4 signaling is dispensable for acute itch, regardless of histaminergic and nonhistaminergic itch.
Tlr4 and spinal TLR4 are required for the development of chronic itch
Dry skin, caused by skin dehydration, is associated with several chronic itch conditions, such as atopic dermatitis and xerosis [18] . We treated mice with acetone and diethyether followed by water (AEW) on neck or cheek skin for 5 days to mimic the symptoms of dry skin in patients [42] . Five days after AEW treatment, WT mice showed robust spontaneous scratching on day 6 (56.7 ± 6.6 scratches/hour; Fig. 1E ), which was Fig. 1E ). Notably, AEWinduced chronic itch on day 6 was also compromised in mice lacking Myd88 (16.8±2.3 scratches/hour; Fig. 1E ). AEW-induced chronic itch in both neck and cheek models was also largely inhibited by intrathecal injection of LPS-RS (Fig. 1E ).
To validate a critical role of TLR4 in chronic itch, we generated an allergic contact dermatitis mouse model by application of hapten 2,4-dinitrofluorobenzene (DNFB). After initial sensitization, treatment of DNFB on day 1, 3, 5, and 7 induced robust spontaneous itch on day 8, which was substantially reduced in Tlr4 −/− mice (Fig.   1F ). Additionally, we tested the involvement of TLR4 in dermatitis-induced chronic itch.
Treatment with diphenylcyclopropenone (DCP) was shown to induce contact dermatitis-associated chronic itch [64] . DCP-treated WT mice exhibited robust and persistent itch for more than 2 weeks, but the development of persistent itch was compromised in Tlr4 −/− mice (P<0.05, two-way ANOVA, Fig. 1G ). Collectively, our results suggest that TLR4 is critically involved in chronic itch after dry skin injury, allergic contact dermatitis, and atopic dermatitis.
TLR4 is required for compound 48/80 and AEW-induced alloknesis
Alloknesis (touch-evoked itch) is induced by light touch at the skin near an itchy site.
Scratching responses following intradermal injection of compound 48/80 declined over a 30-min period. Immediately after that period, alloknesis score was assessed by counting the number of bouts of scratching following application of 0.7 mN von Frey stimuli [5] .
Tlr4
−/− mice displayed a significant reduction in alloknesis score during a 60 min period (i.e., 30-90 min after the compound 48/80 injection, Fig. 2A ). Intrathecal LPS-RS inhibited compound 48/80-induced alloknesis (Fig. 2B) . Alloknesis was also induced after AEW treatment (dry skin) in WT mice, beginning on day 1 and reaching to a high level on day 5 (Fig. 2C) . Notably, AEW-induced development of alloknesis was reduced in Tlr4 −/− mice (Fig. 2C) . Furthermore, dry skin-induced alloknesis in both neck and cheek models was substantially inhibited by intrathecal LPS-RS (Fig. 2D) . Together, these data demonstrate that TLR4 is critically involved in alloknesis after acute itch and also during chronic itch.
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Intrathecal LPS enhances acute pain, alloknesis, and chronic itch but suppresses acute itch
To study the relationship between pain and itch, we further tested whether direct activation of peripheral and spinal TLR4 with LPS would affect pain or itch. Whole cell patch-clamp recordings in dissociated small-sized DRG neurons showed that LPS, even at a very high concentration (100 mg/ml), failed to induce inward currents (Fig. 3A ) and action potentials (Fig. 3B) . As positive control, capsaicin (100 nM) induced marked inward currents and actions potentials in the same recorded neurons (Fig. 3A,B) .
Therefore, LPS cannot directly excite nociceptive/pruriceptive neurons in the peripheral nervous system. Consistently, intradermal injection of LPS (10 µg) did not induce scratching behavior in mice (data not shown).
Next, we examined the central effects of LPS on pain and itch. Intrathecal LPS (10 µg) induced heat hyperalgesia, as revealed by a reduction in response latency 24 h after the LPS injection (Fig. 3C) . Moreover, intrathecal LPS did not evoke scratching behavior (data not shown). Interestingly, intrathecal LPS suppressed compound 48/80
and CQ-induced acute itch (Fig. 3D ), but enhanced compound 48/80-induced alloknesis (Fig. 3E) . Further, intrathecal LPS enhanced AEW-induced chronic itch (Fig. 3F ).
Together, these data suggest that activation of spinal TLR4 can (1) evoke pain but not itch, (2) suppress acute itch, and (3) enhance alloknesis and chronic itch.
AEW-induced skin pathology is not compromised after Tlr4 deletion
We also examined whether AEW-induced skin pathology would be affected in Tlr4 −/− mice. Histological evaluation in the AEW-treated nape skin revealed that the thickness of epidermis and dermis significantly increased in both WT and Tlr4 −/− mice following AEW treatment, and no difference in skin thickness was found between genotypes ( Fig. S1A,B) . The total number of immune cells in the skin (including both epidermis and dermis) was also significantly increased in dry skins of both WT and Tlr4 −/− mice (Fig. S1A,B) . We also checked the number of mast cells with Toluidine blue staining in control and dry skins and found that the number of mast cells was unaltered following dry skin injury, in agreement of a previous report [42] . Neither did Tlr4 −/− mice show changes in mast cells before or after skin injury (Fig. S1A,B) . Together, these data
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suggest that TLR4 plays no major role in skin pathology. However, Tlr4 expression was increased in dry skins 5 days after the AEW treatment (Fig. S1C) , indicating that peripheral TLR4 might regulate chronic itch via a different mechanism.
TLR4 is upregulated and essential for spinal astrocyte activation in chronic itch
To assess glial changes in chronic itch, we employed immunohistochemistry to examine microglia and astrocyte activation (gliosis, a robust and persistent activation state of glial cells) in the spinal cord dorsal horn in a dry skin condition. GFAP and IBA-1 are two of the most frequently used markers for astrogliosis (GFAP) and microgliosis (IBA-1) in the spinal cord dorsal horn and show dramatic changes in neuropathic pain [25] . AEW treatment in nape for 5 days significantly increased the expression of GFAP but not IBA-1 in the cervical dorsal horn, and moreover, the GFAP upregulation was abolished in (Fig. 4A,B) . Western blot analysis in cervical dorsal horn tissues further confirmed the TLR4-dependent GFAP increase 5 days after the AEW treatment (Fig. 4C ).
Of interest, basal GFAP expression was not affected in Tlr4 −/− mice ( Fig. 4A-C) . In contrast, compound 48/80 failed to increase GFAP expression in both WT and Tlr4 −/− mice ( Fig. S2A-C) . Furthermore, intrathecal LPS-RS also reduced AEW-induced GFAP expression (Fig. S3A-C) . Collectively, these results suggest that chronic itch but not acute itch is associated with TLR4-dependent astrogliosis in spinal cord.
To determine whether scratching is essential for astrogliosis in chronic itch, we used Elizabethan collar to protect mice from scratching the AEW-treated cheek skin. Dry skin-induced astrogliosis in the cervical spinal cord (C1-C2) was prevented by mouse wearing of Elizabethan Collar (Fig 5A-C) . Thus, scratching could promote chronic itch by inducing astrogliosis.
To localize TLR4 expression in the dorsal horn, we conducted double immunostaining in the spinal cord of AEW-treated mice. Fig. 6 shows that both TLR4
and GFAP-immuno-reactivity (IR) were increased in cervical spinal cord (C3-C4) 5 days after AEW treatment, especially in the ipsilateral side of the dorsal horn (Fig. 6A,B) .
Notably, there was more co-localization of TLR4 and GFAP in the dry skin condition.
TLR4 was primarily localized in GFAP-expressing astrocytes after AEW treatment, although TLR4 was also expressed in other cell types (Fig. 6C) .
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We employed quantitative PCR (qPCR) analysis to examine the time courses of glia-related gene expression in the spinal dorsal horn 1, 3, and 5 days after AEW treatment. AEW induced rapid and persistent Tlr4 mRNA expression at all the time points (Fig. 7A) . AEW also induced delayed Gfap expression and rapid but transient
Iba1 expression (Fig. 7A) . Together, these data further support the involvement of spinal TLR4 and astrocytes in chronic itch. As expected, AEW-evoked Gfap expression was also abrogated after Tlr4 deletion (Fig. 7B ).
Next, we tested if TLR4 activation is sufficient to produce spinal glial changes.
Intrathecal LPS resulted in significant increases in Tlr4 and Gfap mRNA expression in cervical spinal cord (Fig. 7C) . However, the increase in Iba1 expression after LPS treatment was statistically insignificant (P=0.09, Fig. 7C ).
Spinal astrocyte activation contributes to chronic itch and alloknesis not acute itch
L-alpha aminoadipate (L-AA) is an astroglial toxin and has been shown to inhibit astrogliosis and neuropathic pain [70] . Intrathecal administration of L-AA had no effect on compound 48/80 and CQ-induced acute itch (Fig. 8A) . However, intrathecal L-AA effectively inhibited compound 48/80-induced induced alloknesis (Fig. 8B ) and AEWinduced chronic itch and alloknesis (Fig. 8C, D) . Together, these results support an active role of spinal cord astrocytes in alloknesis and chronic itch.
Discussion
TLR3, TLR4, and TLR7 play distinct roles in itch
In the past decade, great progress has been made in identifying itch-specific receptors and agonists, TLR4 agonist LPS failed to induce inward currents and action potentials in DRG neurons (Fig. 3A,B ) and evoke scratching behavior in mice. However, it was also shown that Tlr4 deficiency lead to a reduction in histamine-induced itch due to reduced TRPV1 expression in primary sensory neurons [40] .
Spinal astrocytes have different roles in acute and chronic itch
Although spinal astrocytes have been strongly implicated inflammatory and neuropathic pain [17;25;59;62] , their involvement in acute and chronic itch remains largely unknown. lasting pain hypersensitivity and glial activation in experimental arthritis [1] . It will also be of great interest to investigate the possible role of HMGB1 in chronic itch. An interesting observation of this study is that AEW-induced astrogliosis in spinal dorsal horn could be blocked by preventing mouse from scratching using Elizabethan Collar.
Thus, scratching-induced sensory input (presumably nociceptive afferent input) is essential for astrogliosis in the dry skin model. Consistently, cutting the nails of mouse can also prevent astrogliosis in atopic dermatitis [53] , suggesting that scratching induced noxious afferent input might be critical to drive astrogliosis (reactive changes of astrocytes). These results also suggest that scratching could promote chronic itch by inducing astrogliosis, as an important mechanism underlying itch-scratch-itch cycle.
Involvement of TLR4 and astrocyte signaling in alloknesis
Alloknesis, i.e. touch-evoked itch in itchy skin, is commonly seen in chronic itch patients [54] . Alloknesis may result from spinal cord modulation (central sensitization), since activation of low-threshold mechanoreceptors excites sensitized itch-signaling neurons in the dorsal horn [5] . We are the first to demonstrate that spinal cord astrocytes play a role A C C E P T E D in alloknesis. Our data showed that TLR4 and astroglial activation were both required for alloknesis after compound 48/80-induced acute itch and during AEW-induced chronic itch. This study also showed that AEW but not compound 48/80 induced GFAP upregulation, indicating that chronic itch but not acute itch is associated with astrogliosis in spinal cord. However, intrathecal injection of astrocyte inhibitor L-AA still suppressed alloknesis, suggesting that astrocyte activation could also be involved in the development of alloknesis. Thus, we speculated that distinct activation states of astrocytes may differentially regulate acute and chronic itch: astrocyte activation without astrogliosis regulates alloknesis after acute itch, whereas astrogliosis is involved in chronic itch.
Further studies are necessary to dissect out signaling pathways that mediate different activation states in astrocytes. Compared to mechanical allodynia, a painful response induced by low-threshold mechanical stimulation, both alloknesis and mechanical allodynia can be operated by central sensitization, which is driven by activation of TLR4
and astrocytes. On the other hand, alloknesis and allodynia are distinct behaviors:
mechanical allodynia is a withdrawal response, whereas alloknesis is a scratching response.
Concluding remarks
Our findings demonstrate that spinal cord TLR4 and astroglial signaling play an important role in chronic itch and allokensis without affecting acute itch. Given a wellknown role of TLR4 and astrocyte signaling in chronic pain, our results suggest that chronic pain and chronic itch share similar mechanisms such as central sensitization.
While scratching can relieve acute itch via a spinal cord circuit [12] , it can also provoke chronic itch, and an itch-scratch-itch cycle can often be seen in chronic itch patients.
Notably, scratching-induced astrogliosis can promote chronic itch. Although our data support a central mechanism of TLR4 signaling in itch control, we should not ignore the peripheral role of TLR4 expressed by other cell types in diverse skin diseases, such as mast cells, keratinocytes, and immune cells [14;46] . Despite the fact that scratching is substantially reduced in Tlr4 KO mice, the residue scratching may still be sufficient to cause skin pathology after AEW treatment in KO mice, since we did not put Elizabethan Collar on these mice to prevent them from scratching the itchy skin. Future studies are
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needed to fully investigate the pathological changes as well as biochemical changes (expression of itch mediators and inflammatory mediators such as cytokines and chemokines) in skins of WT and KO mice with and without Elizabethan Collars. Since TLR4 is upregulated in dry skin, it is possible that TLR4 may regulate the expression of certain cytokines and chemokines to facilitate chronic itch, despite the fact we did not see obvious changes in AEW-induced skin pathology in Tlr4 −/− mice. In future study, conditional deletion of Tlr4 in keratinocytes and mast cells will help to address this question.
Chronic itch remains a major health problem in skin diseases such as atopic dermatitis (AD), contact dermatitis, allergic contact dermatitis and xerosis [66] . It also occurs in systemic diseases such as cholestatic liver diseases, kidney diseases (e.g. uraemia), and diabetes [28] . To date, there are still lack of mechanism-based therapies for chronic itch [66] and antihistamines do not work for most chronic itch conditions [61] .
Therefore, targeting TLR4 and glial signaling may provide novel anti-itch therapies.
Notably, there are established links between Tlr polymorphisms and individual susceptibility to chronic itch diseases in human [43;49] , and glial activation has been implicated in human pain conditions [37;51] , supporting translational potential of our preclinical findings.
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